P-Carzine 50 mg Procarbazine Tablets (1 pack / 50 tabs)

At a Glance

Generic Name: Procarbazine Hydrochloride

Brand Name: P-Carzine 50 mg

Strength & Pack Size: 50 mg tablets, 1 pack / 50 tablets

Dosage Form & Route: Oral tablets taken by mouth

Therapeutic Class: Alkylating-type cytotoxic agent (antineoplastic)

Primary Indications: Hodgkin lymphoma and selected primary brain tumours, as part of combination chemotherapy regimens

Typical Use in Therapy: Used in multi-drug protocols (such as MOPP- or PCV-type regimens) under specialist haematology–oncology supervision

Mode of Action: Interferes with DNA, RNA and protein synthesis in rapidly dividing malignant cells

Key Benefits: Well-established component of recognised chemotherapy schedules in appropriately selected patients

Precautions: Requires close monitoring of blood counts, liver function, nervous system effects, interactions and secondary malignancy risk

Storage: Store in the original carton below 25 °C, protected from moisture and out of the reach of children

Product Description

P-Carzine 50 mg contains procarbazine hydrochloride, an oral chemotherapy agent used as part of established combination regimens for Hodgkin lymphoma and certain primary brain tumours. Unlike many IV chemotherapies, procarbazine is taken by mouth as tablets but still acts as a potent anticancer medicine that must be handled and monitored with the same level of care as injectable cytotoxics.

Each pack of P-Carzine 50 mg procarbazine tablets supplied by Generic Meds Mart contains 50 tablets, typically used across several days within repeating chemotherapy cycles according to protocol. Procarbazine is rarely used alone; instead, it is combined with other agents such as alkylating drugs, vinca alkaloids, corticosteroids or nitrosoureas in regimens designed by specialist teams. The exact schedule, total number of cycles and supportive medicines are always determined by the treating haematologist or oncologist based on the official prescribing information and current clinical guidance.

Generic Meds Mart works only with licensed oncology manufacturers and authorised distributors when sourcing P-Carzine 50 mg procarbazine tablets. Each pack is provided in its original sealed carton with visible batch and expiry details so hospital and clinic pharmacies can verify the medicine before dispensing. Shipments are sent in neutral outer packaging without explicit references to lymphoma, brain tumours or chemotherapy on the label, helping protect patient privacy while preserving full documentation for healthcare teams. Our role is limited to access and logistics; complex choices about whether and how to use procarbazine rest solely with your specialist.

Key Uses

P-Carzine 50 mg procarbazine tablets are used within systemic treatment plans for selected malignancies, in line with local labelling and evidence-based protocols. Typical uses include:

• Hodgkin lymphoma, where procarbazine may be part of multi-agent regimens in specific lines of therapy.
• Primary brain tumours such as certain high-risk gliomas, often as part of PCV-type (procarbazine, lomustine, vincristine) protocols where appropriate.
• Other specialist-indicated scenarios where procarbazine-containing combinations have been selected by the oncology team.

The decision to use P-Carzine 50 mg, and in which regimen, depends on tumour type and stage, prior therapy, patient age, organ function, performance status and the availability of alternative options.

How Procarbazine Works in Chemotherapy

Procarbazine, the active ingredient in P-Carzine 50 mg, is an alkylating-type antineoplastic agent. After absorption, it undergoes metabolic activation and generates reactive intermediates that interact with cellular macromolecules, including DNA, RNA and proteins. These interactions can lead to alkylation, strand breaks and mispairing events in DNA, interfering with replication and transcription in rapidly dividing cells.

By damaging tumour cell DNA and disrupting essential cellular processes, procarbazine contributes to cell-cycle arrest and apoptosis in sensitive malignant populations. When combined with other cytotoxic agents that act through complementary mechanisms, procarbazine-based chemotherapy regimens help create multi-pronged treatment strategies that increase the likelihood of long-term disease control or cure in selected Hodgkin lymphoma and brain tumour patients.

Dosage & Administration

P-Carzine 50 mg procarbazine tablets must only be prescribed and supervised by experienced haematologists or oncologists. Dosing is usually expressed in mg per square metre of body surface area or as mg per kg and may vary across treatment days within a cycle. Procarbazine is commonly taken once or multiple times daily for a defined period (for example, several consecutive days) followed by a rest phase before the next cycle, but the exact schedule differs significantly between protocols.

Tablets are swallowed whole with water and should generally not be crushed or chewed. Food and alcohol restrictions may apply, as procarbazine can interact with certain foods and beverages; the treating team and patient leaflet provide specific guidance. Blood counts and organ function tests are performed regularly, and doses may be adjusted, delayed or stopped depending on toxicity, response or intercurrent illness. Patients must never change the dose or schedule on their own.

Precautions

Before starting P-Carzine 50 mg, the oncology team will carefully review medical history, prior treatments, liver and kidney function, neurological status, infection risk and concomitant medicines. Procarbazine can cause significant myelosuppression, raising the risk of serious infection and bleeding, and has been associated with an increased risk of secondary malignancies over the long term. Patients should be counselled on measures to reduce infection risk and on the importance of reporting fever, bruising, bleeding or unusual symptoms promptly.

Interactions with certain foods, alcohol and other medicines need special attention. Procarbazine has monoamine oxidase (MAO)–inhibiting properties, so tyramine-rich foods and some medicines can provoke hypertensive reactions. Effective contraception is strongly recommended for people of childbearing potential during treatment and for a period afterwards, as procarbazine may harm a developing fetus and can affect fertility. Breastfeeding is generally not recommended while taking P-Carzine 50 mg.

Procarbazine Side Effects

Common side effects

Common procarbazine side effects in patients receiving P-Carzine 50 mg include nausea, vomiting, loss of appetite, weight loss, fatigue, headache, mild dizziness, constipation or diarrhoea, and changes in taste. Myelosuppression with reduced white blood cell counts, red blood cell counts and platelets is very frequent and often dose-limiting. Some patients experience mild neurological symptoms such as tingling, mood changes or difficulty sleeping, as well as skin rashes or hair thinning. These effects may be manageable with supportive medicines, dietary adjustments, dose changes and careful cycle-by-cycle monitoring.

Serious side effects

Serious procarbazine adverse effects require urgent medical attention and may include severe or febrile neutropenia with life-threatening infections, profound thrombocytopenia with bleeding, significant anaemia, marked liver dysfunction, severe neurological changes, hypertensive crises related to interactions, allergic reactions and, over the long term, the potential development of secondary malignancies such as acute leukaemia. Warning signs include high or persistent fever, chills, severe sore throat, shortness of breath, uncontrolled bleeding or bruising, black or bloody stools, confusion, severe headache, chest pain, seizures, sudden vision changes, dark urine, yellowing of the skin or eyes or very severe fatigue.

Any new or rapidly worsening symptom during treatment with P-Carzine 50 mg procarbazine tablets must be reported immediately to the treating team, and patients should seek emergency care if serious warning signs appear.

Storage

P-Carzine 50 mg procarbazine tablets should be stored in their original blister and carton, below 25 °C, protected from moisture and direct heat. Tablets should be kept out of sight and reach of children and must not be transferred into unlabelled containers. The medicine should not be used after the expiry date printed on the pack. Unused or expired procarbazine tablets and any materials contaminated with cytotoxic residues should be returned to a pharmacy or disposed of via approved oncologic waste channels, not in household rubbish or wastewater.

Why Buy from Generic Meds Mart

Generic Meds Mart is focused on structured, traceable access to essential chemotherapy medicines such as P-Carzine 50 mg procarbazine tablets. We partner only with licensed manufacturers and authorised oncology wholesalers that comply with recognised quality standards and maintain verifiable batch records. Each pack of P-Carzine 50 mg is supplied in sealed original packaging so hospital and clinic pharmacies can confirm brand, strength, batch number and expiry before dispensing.

Orders are processed in USD via secure checkout, and parcels are shipped in discreet, neutral outer packaging without references to Hodgkin lymphoma, brain tumours or chemotherapy on the label. Where available, trackable delivery options help patients and clinics coordinate chemotherapy scheduling so that tablets are on hand before the planned cycle start. Our role is limited to procurement and logistics; all medical decisions about indications, regimens, dose adjustments and treatment duration remain the responsibility of your specialist team.

Order Now

Before you buy P-Carzine 50 mg online from Generic Meds Mart, you should have a clearly documented treatment plan from your haematologist or oncologist that explains why a procarbazine-containing regimen is appropriate for your Hodgkin lymphoma or brain tumour, which other agents it will be combined with, how many cycles are planned and what monitoring will be used. Your team will outline expected benefits, possible risks and which symptoms require immediate attention.

Once this plan is agreed, you or your clinic can determine how many packs of P-Carzine 50 mg (1 pack / 50 tabs) are needed for the initial cycles. You can then select the appropriate quantity, add them to your cart and complete secure checkout in USD. Medicines will be dispatched in discreet packaging with documentation including product name, strength and batch details. You should never start, stop or change procarbazine therapy without specialist guidance, and any concerning symptom during treatment should prompt prompt contact with your oncology team.

FAQ about P-Carzine (Procarbazine)

Q1: What is P-Carzine 50 mg used for?
P-Carzine 50 mg contains procarbazine hydrochloride, an oral chemotherapy agent used as part of combination regimens for Hodgkin lymphoma and certain primary brain tumours, according to local prescribing information and specialist protocols.

Q2: Is P-Carzine 50 mg taken at home or in hospital?
P-Carzine 50 mg tablets are usually taken at home as part of a planned cycle, but they are prescribed, monitored and adjusted by hospital-based haematology–oncology teams. Regular clinic visits and blood tests remain essential to ensure safe use.

Q3: Can I drink alcohol or eat normally while on procarbazine?
Procarbazine has MAO-inhibiting properties, so alcohol and particular foods or drinks can trigger dangerous reactions. Your team and patient leaflet will give a list of items to avoid during treatment. You should follow this guidance strictly and check with your doctor or pharmacist if in doubt.

Q4: Will I lose my hair with P-Carzine 50 mg?
Some patients notice hair thinning while on procarbazine-containing regimens, but the degree of hair loss varies and often depends on the full combination of drugs being used. Your oncology team can provide more personalised expectations based on your overall protocol.

Q5: How long will I need to take P-Carzine 50 mg?
Procarbazine is usually given for a defined number of cycles as part of a larger regimen. The total duration depends on your diagnosis, stage, treatment goals, response and tolerability. Only your treating specialist can decide how many cycles of P-Carzine 50 mg are appropriate for you.

Alsatinib 100 mg Dasatinib Tablets (1 bottle – 30 tablets)

At a Glance

Generic Name: Dasatinib

Brand Name: Alsatinib 100 mg

Strength & Pack Size: 100 mg tablets, 1 bottle – 30 tablets

Dosage Form & Route: Oral film-coated tablets taken by mouth

Therapeutic Class: BCR-ABL tyrosine kinase inhibitor (TKI)

Primary Indications: Chronic myeloid leukemia (CML) and Philadelphia chromosome–positive acute lymphoblastic leukemia (Ph+ ALL), as per local label

Usual Adult Dose: As directed by your haematologist or oncologist based on indication and official prescribing information

Mode of Action: Inhibits BCR-ABL and related kinases that drive leukemic cell proliferation and survival

Key Benefits: Targeted therapy option in CML and Ph+ ALL, used within modern haematology treatment protocols

Precautions: Requires specialist supervision, regular blood tests, ECG and careful review of comorbidities and co-medications

Storage: Store below 25 °C in the original bottle, tightly closed and protected from moisture and light

Product Description

Alsatinib 100 mg is a dasatinib-based oral tyrosine kinase inhibitor (TKI) used as part of targeted haematology therapy in selected patients with chronic myeloid leukemia (CML) and Philadelphia chromosome–positive acute lymphoblastic leukemia (Ph+ ALL). Dasatinib is designed to inhibit BCR-ABL and certain other kinases that are abnormally active in these leukemias, and has become an important component of modern treatment strategies alongside other TKIs and disease-monitoring techniques.

Each bottle of Alsatinib 100 mg dasatinib tablets contains 30 film-coated tablets, providing a convenient supply for once-daily or protocol-defined dosing schedules. The exact use of Alsatinib 100 mg depends on your diagnosis, disease phase, prior treatments and local prescribing information. It is only prescribed by experienced haematologists or oncologists familiar with BCR-ABL–positive leukemias, molecular monitoring and the safety profile of dasatinib.

Generic Meds Mart supplies Alsatinib 100 mg dasatinib tablets in original manufacturer packaging sourced from licensed oncology and haematology distributors. Bottles and cartons display the brand name, strength, generic name, tablet count, batch number, expiry date and storage instructions so hospital pharmacies, clinics and patients can verify the product. Orders are dispatched in neutral outer packaging that does not mention leukemia or targeted therapy, maintaining privacy while preserving full batch traceability. Our role is focused on access and logistics; all clinical decisions remain with your specialist team.

Key Uses

Alsatinib 100 mg dasatinib tablets are used in the management of BCR-ABL–positive leukemias where a tyrosine kinase inhibitor has been recommended. Depending on the local label, guidelines and treating physician’s judgment, Alsatinib may be used in:

• Chronic myeloid leukemia (CML) in chronic, accelerated or blast phase in patients who are newly diagnosed or who are intolerant of, or resistant to, prior therapy with other TKIs.
• Philadelphia chromosome–positive acute lymphoblastic leukemia (Ph+ ALL) as part of combination treatment regimens and longer-term maintenance protocols according to specialist protocols.

The decision to use Alsatinib 100 mg is based on a careful assessment of your disease phase, BCR-ABL status, prior treatment history, co-existing health conditions and potential interactions with other medicines. It is not intended for general use in other cancers or haematologic disorders unless explicitly specified in your local prescribing information and specialist guidelines.

How Dasatinib Works in Chemotherapy

Dasatinib, the active ingredient in Alsatinib 100 mg, is a second-generation BCR-ABL tyrosine kinase inhibitor. In CML and Ph+ ALL, the BCR-ABL fusion protein drives uncontrolled leukemic cell growth through persistent kinase signalling. Dasatinib binds to the ATP-binding site of BCR-ABL and related kinases, inhibiting their activity and thereby interrupting key downstream pathways that promote proliferation and survival of leukemic cells.

By blocking BCR-ABL kinase signalling, dasatinib can reduce the leukemic cell burden, support restoration of more normal blood cell production and help patients achieve hematologic, cytogenetic and molecular responses. Dasatinib also has activity against other kinases, which contributes both to its therapeutic effects and to some of its side effects. Because responses and tolerability vary between individuals, Alsatinib dasatinib therapy must be closely monitored using regular blood counts, BCR-ABL testing and clinical review.

Dosage & Administration

The dose and schedule of Alsatinib 100 mg dasatinib tablets are determined by your haematologist or oncologist according to indication, disease phase, age, organ function, concomitant medications and official prescribing information. In many adult CML and Ph+ ALL regimens, dasatinib is given as a once-daily oral dose, but dose adjustments, temporary interruptions or long-term modifications may be required based on response and side effects.

Alsatinib tablets should be swallowed whole with water and should not be crushed or chewed unless your healthcare team specifically instructs you otherwise. It is important to take Alsatinib at the same time each day and to follow any directions about taking it with or without food. If you miss a dose, you should follow the advice in your patient leaflet or from your clinic and avoid taking extra tablets without medical guidance. You must not change the dose or stop dasatinib on your own; any modifications should be supervised by your specialist, who will use blood tests and molecular monitoring to guide decisions.

Precautions

Before starting Alsatinib 100 mg, your medical team will review your full medical history, including heart and lung function, liver and kidney status, risk of bleeding, prior or current fluid accumulation around the lungs (pleural effusion) and any previous TKI exposure. Dasatinib can interact with other medicines, particularly those that affect liver enzymes or gastric pH, so it is essential to provide a complete list of prescription drugs, over-the-counter products and herbal supplements to your care team.

Regular monitoring is required during Alsatinib therapy and typically includes blood counts, liver and kidney function tests, ECGs and, in some cases, chest imaging to assess for fluid accumulation. Women and men of childbearing potential are usually advised to use effective contraception during dasatinib treatment and for a period after it ends, because targeted anticancer medicines may harm a developing baby. Breastfeeding is generally not recommended while taking dasatinib.

Your specialist will explain which precautions apply in your situation.

Dasatinib Side Effects

Common side effects

Common dasatinib side effects can include headache, fatigue, nausea, diarrhoea, decreased appetite, mild abdominal discomfort, rash or dry skin, mild bleeding or bruising, and musculoskeletal pain. Some patients experience fluid retention such as ankle swelling, periorbital puffiness or mild weight gain. Blood tests may show reductions in white cells, red cells or platelets, as well as mild changes in liver function or electrolytes.

These effects are often manageable with supportive medications, careful monitoring and, in some cases, dose adjustments or short treatment interruptions. It is important to report any new or troublesome symptoms to your haematology team promptly so they can decide whether supportive care, additional tests or a change in dasatinib dosage is needed.

Serious side effects

Although less common, serious dasatinib adverse effects require urgent medical attention. These may include severe myelosuppression with high risk of infection or bleeding, significant fluid accumulation around the lungs (pleural effusion) or heart, shortness of breath, chest pain, serious bleeding events, marked prolongation of the QT interval on ECG, sudden palpitations, severe liver injury or other organ complications.

Warning signs that should prompt immediate medical review include high fever, chills, persistent cough, increasing breathlessness, chest pain, rapid or irregular heartbeat, severe bleeding, black stools, vomiting blood, sudden confusion, severe abdominal pain, yellowing of the skin or eyes, or marked swelling. If any of these occur while taking Alsatinib 100 mg dasatinib, you should seek emergency care and inform clinicians that you are on a BCR-ABL tyrosine kinase inhibitor.

Storage

Alsatinib 100 mg dasatinib tablets should be stored at room temperature, generally below 25 °C, in their original bottle with the cap tightly closed to protect from moisture and light. Do not transfer tablets to unlabelled containers and keep them out of sight and reach of children and pets. Do not use Alsatinib after the expiry date printed on the carton and bottle. Any unused or expired dasatinib tablets should be returned to a pharmacy or disposed of in line with local guidance for cytotoxic or targeted anticancer medicines and not thrown into household rubbish or wastewater.

Why Buy from Generic Meds Mart

Generic Meds Mart is focused on supporting access to essential targeted therapies such as Alsatinib 100 mg dasatinib tablets, especially in regions where local supply, pricing or distribution may be challenging. We work only with licensed manufacturers and authorised distributors that follow recognised quality standards and maintain full batch and expiry traceability. By supplying Alsatinib in sealed original packaging, we help clinics and pharmacies verify that the correct brand, strength and batch have been delivered.

All Alsatinib 100 mg orders placed through Generic Meds Mart are processed in USD using secure online checkout. Shipments are prepared in neutral outer packaging without references to leukemia or chemotherapy to protect privacy. Where available, tracked delivery options help patients and haematology teams plan treatment cycles and refills in advance, reducing the risk of interruptions caused by supply issues. Our role is strictly logistical; the choice to use dasatinib, the dose schedule and any treatment modifications are the responsibility of your specialist team.

Order Now

Before you buy Alsatinib 100 mg dasatinib tablets online from Generic Meds Mart, you should already have a confirmed diagnosis of CML or Ph+ ALL, documented BCR-ABL positivity and a written treatment plan from your haematologist or oncologist that specifically includes dasatinib, dose, monitoring strategy and expected duration. Your team will explain how Alsatinib fits alongside other parts of your care such as additional medicines, molecular testing and supportive treatments.

Once this plan is in place, you can select Alsatinib 100 mg, choose the number of bottles that correspond to your specialist’s prescription and complete secure checkout in USD. You should never start, stop or adjust dasatinib without direct medical advice. If you develop new or worsening symptoms such as fever, breathlessness, chest pain, rapid heartbeat, severe bleeding, marked swelling or confusion during treatment, you should seek urgent medical help and inform your care team. Generic Meds Mart exists to support safe, discreet and verifiable supply of Alsatinib 100 mg dasatinib tablets, while all clinical decisions about your leukemia treatment remain with your treating specialists.

FAQ about Alsatinib (Dasatinib)

Q1: What types of leukemia is Alsatinib 100 mg used for?

Alsatinib 100 mg contains dasatinib, a BCR-ABL tyrosine kinase inhibitor used in chronic myeloid leukemia (CML) and Philadelphia chromosome–positive acute lymphoblastic leukemia (Ph+ ALL) according to local prescribing information and specialist guidelines.

Q2: Will I need regular blood tests while taking Alsatinib?

Yes. Regular blood tests are essential during dasatinib therapy to monitor blood counts, liver and kidney function and to check for potential side effects. In addition, molecular tests to measure BCR-ABL levels are often used to assess how well your leukemia is responding to treatment.

Q3: Can I take antacids or acid-reducing medicines with Alsatinib?

Some acid-reducing medicines can affect the absorption of dasatinib. You should tell your haematology team about any antacids, proton pump inhibitors or H2 blockers you use. Your doctors may adjust the timing or choose alternatives to avoid reducing dasatinib exposure.

Q4: Is it safe to become pregnant while on dasatinib?

Dasatinib can be harmful to a developing baby, and pregnancy is generally not recommended while taking Alsatinib 100 mg. Effective contraception is usually required during treatment and for a period after stopping the medicine. If you are pregnant, planning pregnancy or your partner may become pregnant, you must discuss this with your specialist before starting or continuing dasatinib.

Q5: What should I do if I feel short of breath or develop a persistent cough on Alsatinib?

Shortness of breath or persistent cough can be signs of conditions such as pleural effusion or other lung issues associated with dasatinib. If you notice breathing difficulties, new chest discomfort or unexplained cough, you should contact your haematology team promptly or seek emergency care and ensure clinicians know you are taking Alsatinib 100 mg dasatinib.